Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
SK Hynix Bonus Dispute Deepens as Union Rejects Stock-Based Payout Proposal 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
Toyota Raises FY2027 Outlook, Announces ¥1 Trillion Buyback Despite Q1 Profit Dip 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets 
Jetstar to Charge for Overhead Cabin Bags From February 
NEW YORK, March 15, 2018 -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines for patients with rare neurological disorders, today announced that its fourth quarter and full year 2017 financial results will be released after the market closes on Thursday, March 29, 2018. Following the release, Ovid will host a live conference call and webcast at 5:00 p.m. ET to review the company’s financial results and provide a general business update.
The live audio webcast may be accessed by visiting the Investors section of the company's website at investors.ovidrx.com. Please connect at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. Alternatively, please call (866) 830-1640 (U.S.) or (210) 874-7820 (international) to listen to the live conference call. The conference ID number for the live call is 3387007. An archive of the webcast will be available for two weeks on the company’s website.
About Ovid Therapeutics
Ovid Therapeutics (NASDAQ:OVID) is a New York-based biopharmaceutical company using its BoldMedicine™ approach to develop therapies that transform the lives of patients with rare neurological disorders. Ovid’s drug candidate, OV101, is currently in development for the treatment of Angelman syndrome and Fragile X syndrome. Ovid initiated the Phase 2 STARS trial of OV101 in people with Angelman syndrome in 2017 and completed a Phase 1 trial in adolescents with Angelman syndrome or Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of epileptic encephalopathies and in 2017 initiated a Phase 1b/2a trial of OV935.
For more information on Ovid, please visit http://www.ovidrx.com/.
Ovid Contacts:
Investors:
Burns McClellan
Steve Klass, 212-213-0006
[email protected]
Media:
W2O Pure
Katie Engleman, 910-509-3977
[email protected]
